126
Participants
Start Date
June 8, 2016
Primary Completion Date
November 23, 2016
Study Completion Date
December 23, 2016
CD101 Vaginal Gel (3%)
CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
CD101 External gel (1%)
CD101 external gel (1%) applied topically twice daily over 72 hours as needed
CD101 Vaginal Ointment (6%)
CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
CD101 External ointment (1%)
CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
Fluconazole
oral fluconazole (150mg) on Day 1
ProHEALTH Care Associates, LLP, Port Jefferson
Drexel University College of Medicine, Philadelphia
Tidewater Clinical Research, Inc, Norfolk
Hawthorne Medical Research Inc, Winston-Salem
Unified Women's Clinical Research - Hickory, Winston-Salem
Eastern Carolina Women's Center, New Bern
Augusta University, Augusta
New Age Medical Research Corporation, Miami
Altus Research Inc, Lake Worth
Olympian Clinical Research, Clearwater
Women's Medical Research, Clearwater
University of Alabama at Birmingham, Birmingham
Aventiv Research Inc, Columbus
Tolan Park Clinic, Detroit
Saginaw Valley Medical Research Group LLC, Saginaw
Clinical Trials Management LLC, Metairie
The Women's Clinical, P.A., Little Rock
TMC Life Research Inc., Houston
Clinical Trials of Texas Inc, San Antonio
Precision Trials AZ LLC, Phoenix
Women's Health Care Research Corp, San Diego
Seattle Women's Health, Research, Gynecology, Seattle
Lawrence OB GYN Clinical Research LLC, Lawrenceville
Alliance Women's Research Group LLC, Riverside Park
Lead Sponsor
Cidara Therapeutics Inc.
INDUSTRY